J Korean Pediatr Soc Search

CLOSE


Journal of the Korean Pediatric Society 1992;35(3):371-380.
Published online March 15, 1992.
Ifosfamide in the Pediatric Malignant Solid Tumors
Sang Wook Choi
Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea
소아 악성 고형종양에 대한 Ifosfamide의 효과
최상욱
원자력병원 소아과
Abstract
Ifosfamide (IFO), one of a number of alkylating agents, has been given with Adriamycin (ADR) or Etopsoide (VP-16) to the thirteen malignant solid tumor patients (five neuroblastoma, six osteosarcoma, one rhabdomyosarcoma, one leigomyosarcoma). IFO 1.8g/m2/d was given for an hour with mensa uroprotection for the consecutive five days. All but two relapsed patients had response. The number of courses were ranged from one to seven, and the internal between them was 3-4 weeks. Most patients tolerated the treatment well. The response was CR 1, PR 9, and the total response rate was 76.8%. The major toxicity was mild to moderate degree of naused and vomiting (84.6%), ketonuria (84.6%), anemia (69.2%) leukopenia (53.8%), proteinurial (46.2%), thrombocytopenia (38.5%), fever (38.5%), hepatotoxicity (15.4%) and convulsion (15.4%). One patient developed transient convulsive disorder, but hemorrhagic cystitis was not found. Although it is a study in the single instituion with small number of patients, IFO may be a promisng first line agent to the pediatric malignant solid tumor.
Key Words: Ifosfamide, Solid tumors, Toxicity


ABOUT
TOPICS

Browse all articles >

ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
AUTHOR INFORMATION
Editorial Office
#1606 Seocho World Officetel, 19 Seoun-ro, Seocho-ku, Seoul 06732, Korea
Tel: +82-2-3473-7305    Fax: +82-2-3473-7307    E-mail: kjpped@gmail.com                

Copyright © 2019 by Korean Pediatric Society. All rights reserved.

Developed in M2community

Close layer
prev next